Exercise News and Research

Latest Exercise News and Research

SynCardia Total Artificial Heart recipient celebrates 10 years of life

On Feb. 22, Bill Wohl, a former recipient of the SynCardia temporary CardioWest™ Total Artificial Heart, will celebrate 10 years of enjoying life to the fullest with the donor heart he received at University Medical Center on Feb. 22, 2000.

17 Feb 2010

Patients and doctors differ when it comes to daily health activities

When it comes to daily health activities such as diet and exercise, Americans and their doctors may not always see eye to eye.

17 Feb 2010

Merz Pharma Group completes $5.45 per share cash tender offer for all shares of BioForm Medical

Merz Pharma Group today announced the successful completion of the $5.45 per share cash tender offer for all outstanding shares of BioForm Medical, Inc. made by Merz GmbH & Co. KGaA and its acquisition subsidiary. The tender offer expired at 12:00 midnight, Eastern Standard Time, on February 12, 2010.

17 Feb 2010

Ironwood Pharmaceuticals' IPO: Underwriters exercise over-allotment option

Ironwood Pharmaceuticals, Inc. today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwood’s Class A common stock. With the completion of the IPO and the exercise of the over-allotment option, Ironwood has approximately 97.4 million shares of common stock outstanding (approximately 19.2 million shares of Class A common stock and 78.2 million shares of Class B common stock).

17 Feb 2010

Emphasising emotional benefits of exercise is more effective in promoting physical fitness

Emphasising the emotional benefits of exercise is more effective at increasing levels of physical activity than highlighting traditional health benefits. This is the finding of research published online today, 17th February 2010, in the British Journal of Health Psychology.

17 Feb 2010

Generx clinical development opportunities: bioRASI to assist Cardium

Cardium Therapeutics today announced that it has entered into an agreement with bioRASI, an international contract research organization, to assist Cardium in the evaluation of Generx clinical development opportunities within major newly-industrializing markets in Eastern Europe, Asia and Latin America, for patients with chronic coronary artery disease who are either not optimal candidates for or do not have access to costly angioplasty/stenting or cardiac bypass surgery procedures.

17 Feb 2010

As politics swirl, both sides prepare for health care summit

With the White House health summit quickly approaching, members from both sides of the aisle "are pressing story lines on how the reform debate has played out that aren't as tidy or truthful as Democrats and Republicans would like voters to believe," Politico reports. "The summit could help reset the negotiations, but with [President Barack] Obama, Vice President Joe Biden, other top administration officials and 37 lawmakers all in attendance, the likelihood of a serious breakthrough appears dim."

17 Feb 2010

Fourth-quarter and full-year 2009 results announced by Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2009.

16 Feb 2010

12 minutes of activity a day is all you need to reclaim maximum health

You're hitting the gym four to five times a week. You're dutifully doing the elliptical trainer or treadmill for an hour at a time. But all those long, boring workouts do nothing to strengthen your heart or slim your waistline. Do enough cardio and aerobics and you'll get old before your time.

16 Feb 2010

Aegis Living opens new senior living community in Bellevue

The heart of Bellevue now boasts a new senior living community that is perfectly suited to the needs and desires for residents of the Eastside. Aegis Living, a national leader in senior, assisted living and memory care communities, recently opened its 34th community to a crowd of hundreds, as new and prospective residents and families came to celebrate the grand opening event.

16 Feb 2010

Progressive walking reduces arthritic pain, improves physical function

"Progressive walking" combined with glucosamine sulphate supplementation has been shown to improve the symptoms of osteoarthritis. Researchers writing in BioMed Central's open-access journal Arthritis Research and Therapy found that patients who walked at least two bouts of 1500 steps each on three days of the week reported significantly less arthritis pain, and significantly improved physical function.

16 Feb 2010

Podesta says Obama White House 'lost the narrative' on health bill

"John Podesta, the president of the Center for American Progress who led Barack Obama's presidential transition, acknowledges the White House has been unable to successfully drive the debate on health care reform," Politico reports.

15 Feb 2010

Allele-specific DNA methylation a widespread phenomenon, reveals IoP study

Researchers from the Institute of Psychiatry (IoP), King's College London, have identified numerous novel regions of the genome where the chemical modifications involved in controlling gene expression are influenced by either genetic variation or the parental origin of that particular stretch of DNA. This contradicts previous assumptions that epigenetic signals are generally equal across both copies of a given region of the genome, except at a small number of known imprinted genes.

15 Feb 2010

Synexus takes just ten months to carry out 52,000 DEXA scans

It took clinical trial experts Synexus, just ten months to carry out 52,000 DEXA scans and randomise over 2,700 patients across twelve of their UK, European and African dedicated research centres.

From AES - Accelerated Enrollment Solutions 15 Feb 2010

Bioniche Life Sciences meets obligations under licensing agreement with Endo Pharmaceuticals

Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today announced that it has met the obligations associated with two milestones under its licensing agreement with Endo Pharmaceuticals for exclusive rights to develop and market Bioniche's proprietary product for non-muscle-invasive bladder cancer in North America.

15 Feb 2010

Negative life experiences can harm developing capacity for love

Do you make the same mistakes in love over and over again? For example, do you always seem to pick the wrong partner or always experience the same negative romantic outcome? If so, you need to understand your developmental history of love and break the pattern, according to Dr. Mark Beitel, a licensed clinical psychologist and psychotherapist at Greenwich Hospital's Center for Integrative Medicine in Cos Cob, CT.

15 Feb 2010

Any new pressure in upper body can signal heart attack

Not everyone who suffers a heart attack clutches their chest and falls to the floor. "I woke up and felt like a pill was stuck in my throat," says Betsy, a 68-year-old patient from Upper Providence. "I was taking antibiotics at the time and really didn't think much of it," she adds. "So I tried drinking water and when the "stuck" feeling didn't go away after 45 minutes, I thought something might be wrong."

15 Feb 2010

Labopharm prices underwritten public offering of 11.7M units

Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.

15 Feb 2010

Positive interim results from Helix BioPharma's Topical Interferon Alpha-2b Phase II pharmacokinetic study

Helix BioPharma Corp. today announced that the first ten patients that have been enrolled in its Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions have completed the pharmacokinetic primary endpoint analyses with positive findings.

14 Feb 2010

Viral Genetics: Company update

Our mission is to bring new drug compounds to the marketplace. And we've never been in a stronger position to deliver on that promise. We've built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer to clinical trials.

12 Feb 2010